Lamina I of the spinal dorsal horn is the most superficial layer of the spinal cord gray matter and serves as the primary gateway for nociceptive and thermal information traveling to the brain. The projection neurons located in lamina I are essential for transmitting pain and temperature sensations to higher brain centers, where they are perceived as conscious sensory experiences. These neurons play critical roles in both acute pain processing and in the development of chronic pain states associated with neurodegenerative diseases.
The spinal dorsal horn is organized into a laminar structure (Rexed laminae I-VI), with each lamina containing distinct neuronal populations that process different aspects of somatosensory information. Lamina I, also known as the marginal layer, contains the cell bodies of the primary projection neurons that send axons to brainstem and thalamic targets. This makes lamina I the main output layer for nociceptive information from the spinal cord.
¶ Location and Structure
Lamina I forms the dorsal-most layer of the spinal cord gray matter, immediately below the dorsal column. It is a thin but densely packed layer that wraps around the dorsal horn, extending from the dorsal root entry zone to the dorsal commissure. The laminar boundary is defined by:
- Dorsal boundary: The white matter of the dorsal columns
- Ventral boundary: Lamina II (substantia gelatinosa)
- Lateral extent: The dorsolateral funiculus
- Medial extent: The dorsal commissure
The neuronal population in lamina I is heterogeneous, including both projection neurons and interneurons. Projection neurons constitute approximately 30-40% of the neuronal population, while the remainder are local circuit neurons that modulate incoming sensory information.
Lamina I contains several distinct classes of projection neurons, each with unique anatomical and functional properties:
Spinothalamic Tract (STT) Neurons
The STT is the major pain pathway, carrying information from lamina I neurons to the thalamus:
- Postsynaptic dorsal column neurons: Ascend in the dorsal columns to the nucleus gracilis and cuneatus, then decussate and project to the ventral posterolateral (VPL) nucleus of the thalamus.
- Lateral STT neurons: Cross in the anterior commissure and ascend in the lateral spinothalamic tract to the VPL and other thalamic nuclei.
- Functions: Mediate the sensory-discriminative aspects of pain (location, intensity, quality).
Spinoparabrachial (SPB) Neurons
These neurons project to the parabrachial nucleus in the pons:
- Location: Throughout lamina I, with higher concentration in the lateral portion.
- Projection: Receive input from visceral and somatic nociceptors.
- Functions: Mediate the affective-motivational and autonomic components of pain.
Spinomesencephalic (SMT) Neurons
Project to various brainstem pain-modulating regions:
- Targets: Periaqueductal gray (PAG), nucleus cuneiformis, and other midbrain structures.
- Function: Part of descending pain modulation pathways.
Spinoreticular Neurons
Project to brainstem reticular formations:
- Targets: Reticular formation in the medulla and pons.
- Function: Involved in arousal and autonomic responses to pain.
Lamina I projection neurons exhibit distinct firing patterns that influence their signal transmission:
- Tonic firing: Sustained response to maintained nociceptive input.
- Transient firing: Initial burst followed by accommodation.
- Irregular firing: Variable inter-spike intervals.
These patterns are determined by the expression of specific ion channels and synaptic inputs, and can be modified in chronic pain states.
¶ Receptors and Neurotransmitters
Excitatory receptors
- NMDA receptors: Voltage-dependent, require prior depolarization for activation.
- AMPA receptors: Fast excitatory transmission.
- mGluR1/5: Metabotropic receptors involved in plasticity.
Inhibitory receptors
- GABA-A receptors: Chloride channels, hyperpolarize neurons.
- Glycine receptors: Major inhibitory receptors in spinal cord.
- Presynaptic receptors: Regulate neurotransmitter release.
Neuropeptides
- Substance P: Primary pain transmitter from C-fibers.
- CGRP: Co-released with substance P, enhances transmission.
- N/OFQ: Nociceptin/orphanin, endogenous opioid-like peptide.
Lamina I neurons receive input from primary afferent nociceptors:
A-delta fibers
- Function: Transmit fast, sharp pain (first pain).
- Thermal nociception: Many A-delta fibers respond to noxious heat.
- Mechanical nociception: Some respond to intense mechanical stimuli.
C-fibers
- Function: Transmit slow, burning pain (second pain).
- Polymodal: Respond to thermal, mechanical, and chemical stimuli.
- Silent nociceptors: Normally unresponsive, sensitize in inflammation.
The integration of these inputs in lamina I determines the ultimate pain experience. Temporal summation of C-fiber inputs leads to wind-up, a form of central sensitization.
Central sensitization refers to the enhanced excitability of dorsal horn neurons, including lamina I projection neurons:
Mechanisms
- NMDA receptor activation: Removes Mg2+ block, enhancing transmission.
- Inhibition loss: Reduced GABA/glycine-mediated inhibition.
- Presynaptic facilitation: Increased neurotransmitter release from primary afferents.
- Glial activation: Release of pro-inflammatory cytokines.
Behavioral consequences
- Allodynia: Pain from normally non-painful stimuli.
- Hyperalgesia: Enhanced pain from noxious stimuli.
- Temporal summation: Enhanced response to repetitive stimulation.
This plasticity is thought to underlie the transition from acute to chronic pain.
Lamina I neurons are subject to extensive descending modulation:
Facilitation
- RVM (Rostral ventromedial medulla): On-cells facilitate, off-cells suppress pain.
- 5-HT: Serotonin from RVM can facilitate or inhibit depending on receptor.
Inhibition
- PAG-RVM-dorsal horn pathway: Endogenous opioid-mediated inhibition.
- Noradrenergic inhibition: Alpha-2 adrenergic receptors reduce transmission.
- Dopaminergic modulation: D2 receptors can inhibit pain transmission.
These modulatory systems are altered in chronic pain states and in neurodegenerative diseases.
¶ Parkinson's Disease and Pain
Pain is a common non-motor symptom in Parkinson's disease, affecting up to 50% of patients:
Types of Pain
- Central pain: Direct consequence of dopaminergic degeneration.
- Musculoskeletal pain: Related to rigidity and akinesia.
- Dystonic pain: Associated with motor fluctuations.
- Neuropathic pain: May involve peripheral nerve involvement.
Mechanisms
- Altered pain processing in PD brains involves lamina I and other pain pathways.
- Dopaminergic degeneration affects descending pain modulation.
- Alpha-synuclein pathology may involve spinal cord pain pathways.
Treatment Implications
- Dopaminergic therapy can reduce some types of PD pain.
- Targeting spinal pain circuits may offer novel therapeutic approaches.
- Lamina I function may serve as a biomarker for pain processing in PD.
¶ Alzheimer's Disease and Pain Processing
Alzheimer's disease affects pain processing in complex ways:
Pain Perception Changes
- Altered pain threshold in AD, often elevated in moderate stages.
- Reduced facial expression of pain despite preserved sensation.
- Impaired pain-related learning and memory.
Anatomical Changes
- Amyloid and tau pathology can involve dorsal horn neurons.
- Loss of cortical pain processing areas affects pain perception.
- Cholinergic degeneration affects descending inhibition.
Clinical Considerations
- Pain may be under-recognized in AD patients.
- Changes in pain processing complicate diagnosis.
- Treatment requires consideration of AD-related alterations.
Neuropathic pain is common in ALS:
Prevalence
- Up to 70% of ALS patients experience neuropathic pain.
- Often undertreated due to focus on motor symptoms.
Mechanisms
- Motor neuron degeneration may affect pain pathways.
- Muscle spasm and spasticity contribute to pain.
- Possible involvement of non-motor neurons in disease process.
Treatment
- Standard neuropathic pain medications often ineffective.
- Requires multimodal approach addressing multiple pain mechanisms.
MS involves demyelination and neurodegeneration in spinal cord:
Pain Types
- Neuropathic pain from demyelinated pain pathways.
- Musculoskeletal pain from spasticity.
- Trigeminal neuralgia (more common in MS).
Lamina I Involvement
- Demyelination in dorsal horn affects pain transmission.
- Glial activation contributes to hyperexcitability.
- Loss of inhibition enhances pain signaling.
Nociception in lamina I involves numerous ion channels:
TRP Channels
- TRPV1: Activated by heat >42°C, capsaicin, endogenous ligands.
- TRPA1: Chemical irritants, cold, inflammatory mediators.
- TRPM8: Cold sensation, some analgesic agents.
- TRPV4: Mechanical and thermal stimuli.
Sodium Channels
- Nav1.7: Critical for pain signaling, gain-of-function causes pain disorders.
- Nav1.8: Nociceptor-specific, action potential propagation.
- Nav1.9: Sustained depolarizations, inflammatory pain.
Calcium Channels
- T-type (Cav3.2): Nociceptor excitability.
- N-type (Cav2.2): Neurotransmitter release.
These channels are therapeutic targets for pain medications.
Microglia and astrocytes in the dorsal horn modulate pain:
Microglial Activation
- Pattern recognition receptors detect damage signals.
- P2X4 receptors up-regulated in neuropathic pain.
- Release BDNF, IL-1β, TNF-α, IL-6.
Astrocyte Activation
- Sustained glial response in chronic pain.
- Release cytokines and chemokines.
- Alter glutamate transport.
Neuronal-Glial Communication
- CX3CL1 (fractalkine) from neurons activates microglia.
- CCL2 from neurons recruits microglia.
- This cross-talk maintains pain states.
Chronic pain involves neuroinflammatory processes:
Pro-inflammatory Cytokines
- TNF-α: Enhances neuronal excitability.
- IL-1β: Promotes central sensitization.
- IL-6: Involved in chronic pain development.
Anti-inflammatory Options
- IL-10: Anti-inflammatory, reduced in chronic pain.
- TGF-β: Protective, promotes resolution.
Therapeutic Implications
- Targeting neuroinflammation may treat chronic pain.
- Minocycline (microglial inhibitor) shows some efficacy.
- Novel anti-inflammatory approaches under development.
First-line treatments
- Gabapentinoids: Gabapentin, pregabalin bind to α2δ subunit of calcium channels.
- SNRIs: Duloxetine, venlafaxine for neuropathic pain.
- TCAs: Amitriptyline, nortriptyline for neuropathic pain.
Targeting lamina I transmission
- NMDA receptor antagonists: Ketamine in refractory cases.
- Substance P antagonists: NK1 receptor antagonists.
- TRPV1 antagonists: For inflammatory pain.
Emerging therapies
- Sodium channel blockers: Nav1.7, Nav1.8 selective agents.
- P2X4 antagonists: For neuropathic pain.
- Monoclonal antibodies: Against NGF (tanezumab), CGRP. [@d'Mello2018]
Spinal cord stimulation
- Leads placed in dorsal epidural space.
- Activates dorsal column fibers, reduces pain transmission.
- Effective for failed back surgery syndrome, complex regional pain.
Dorsal root ganglion stimulation
- Targets DRG rather than spinal cord.
- More selective for localized pain.
Motor cortex stimulation
- For refractory facial pain, central pain.
- May modulate thalamic and brainstem pain centers.
Viral vector approaches
- Targeting primary afferent neurons.
- Expressing anti-nociceptive peptides.
- Knocking down pain-related channels.
Future directions
- Cell-type specific targeting.
- Regulated expression systems.
- Combination with other modalities.
- In vivo recordings: From anesthetized animals.
- Ex vivo slice recordings: From spinal cord slices.
- Whole-cell patch clamp: Detailed ionic current analysis.
- c-Fos expression: Activity marker after pain stimulation.
- Calcium imaging: Visualize neuronal activity.
- Tractography: Map spinothalamic pathways in humans.
- Paw withdrawal tests: Measure nociceptive thresholds.
- Formalin test: Model of inflammatory pain.
- CCI model: Chronic constriction injury neuropathic pain model.